GSK (LON:GSK) Announces Quarterly Earnings Results

GSK (LON:GSK) issued its quarterly earnings results on Wednesday. The company reported GBX 46.50 EPS for the quarter, Digital Look Earnings reports. GSK had a net margin of 17.78% and a return on equity of 35.78%. The business had revenue of GBX 762.90 billion for the quarter.

GSK Price Performance

GSK stock opened at GBX 1,904.50 on Friday. The company’s 50-day moving average is GBX 2,084.34 and its 200-day moving average is GBX 1,923.36. The stock has a market capitalization of £76.12 billion, a PE ratio of 13.72, a price-to-earnings-growth ratio of 1.24 and a beta of 0.35. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Citigroup boosted their price objective on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday, February 9th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research note on Tuesday, April 14th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 price target on shares of GSK in a report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Hold” and an average target price of GBX 2,055.71.

Insider Transactions at GSK

In other news, insider Wendy Becker purchased 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The shares were acquired at an average cost of GBX 1,963 per share, with a total value of £78,520. Also, insider Luke Miels sold 15,579 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total value of £336,506.40. Over the last quarter, insiders acquired 15,452 shares of company stock valued at $32,135,952. 0.20% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.